Fundraising FoxOkogen
Plano, US · Founded 2016 · Delaware corporation · 1 known investors
Find your way into Okogen
Sign up to see every warm intro you have to Okogen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Okogen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Okogen is a clinical-stage ophthalmic pharmaceutical company developing a treatment for acute infectious conjunctivitis, covering both bacterial and viral forms. Its lead product is in clinical trials as a single treatment for all forms of the condition.
Founders & leadership
BS
Brian StremExecutive
BC
Bradford ConlanNamed on SEC filing
EJ
Eric J. DanielsNamed on SEC filing
CS
Chris SmithNamed on SEC filing
LR
Leighton ReidNamed on SEC filing
Board
QO
Quinton OswaldBoard director
Investors · 1
Brandon CapitalreportedMelbourne
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.9M disclosed across 3 rounds · 2017–2024
▶$2.5MraisedDec 2024 · 9 investors · OtherRule 506(b)
▶$2.5MraisedDec 2024 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Joshua MoriartyExecutive Officer, Director
- Brian StremDirector, Promoter
- Quinton OswaldDirector
- Bradford ConlanDirector, Promoter
- Eric J. DanielsExecutive Officer, Director, Promoter
- Offering amount
- $2.8M
- Amount sold
- $2.5M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$213KraisedJan 2024 · 4 investors · OtherRule 506(b)
▶$213KraisedJan 2024 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric DanielsDirector
- Quinton OswaldDirector
- Brian StremExecutive Officer, Director
- Bradford ConlanDirector
- Josh MoriartyExecutive Officer, Promoter
- Offering amount
- $594.3K
- Amount sold
- $213K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedDec 2017 · 18 investors · OtherRule 506(b)
▶$6.2MraisedDec 2017 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Brian StremExecutive Officer, Director, Promoter
- Chris SmithDirector
- Leighton ReidDirector
- Eric DanielsExecutive Officer, Promoter
- Bradford ConlanDirector
- Offering amount
- $6.2M
- Amount sold
- $6.2M
- Finders' fees
- $3.3K
- Placement agents
- Marc Gleeson
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Okogen do?
- Okogen is a clinical-stage ophthalmic pharmaceutical company developing a treatment for acute infectious conjunctivitis, covering both bacterial and viral forms. Its lead product is in clinical trials as a single treatment for all forms of the condition.
- Who are Okogen's investors?
- Okogen's investors include Brandon Capital.
- How much funding has Okogen raised?
- Okogen has disclosed $8.9M raised across 3 rounds.
- Where is Okogen headquartered?
- Okogen is headquartered in Plano, US.